Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214506 | 0.94 | MAPK14 (0.34) | KCNH2MAPK14HDAC3KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL215304 | 0.93 | MAPK14 (0.34) | KCNH2MAPK14HDAC3KDM4ELMNA | |
| SCHEMBL214479 | 0.91 | HRH4 (0.41) | KCNH2RPS6KA2OPRL1MAPK14HDAC3 | |
| SCHEMBL214920 | 0.86 | MAPK14 (0.42) | KCNH2MAPK14 | |
| SCHEMBL214523 | 0.83 | MAPK14 (0.35) | KCNH2MAPK14KDM4ELMNAMAPT | |
| SCHEMBL215845 | 0.82 | IRAK4 (0.39) | KDM4ELMNAMAPTRAB9A | |
| SCHEMBL215374 | 0.82 | ABL1 (0.37) | KDM4ELMNAMAPTRAB9A | |
| SCHEMBL215772 | 0.82 | AURKA (0.35) | KCNH2MAPK14 | |
| SCHEMBL214889 | 0.82 | JAK2 (0.39) | MAPK14HDAC3LMNAMAPTRAB9A | |
| SCHEMBL214519 | 0.81 | TBK1 (0.38) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | KCNH2 2774/4885RPS6KA2 268/4885OPRL1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.